Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

被引:5
作者
Das, Sunit [1 ,2 ]
Sahgal, Arjun [3 ]
Perry, James R. [4 ]
机构
[1] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Hosp, Dept Radiat Oncol, Toronto, ON, Canada
[4] Univ Toronto, Sunnybrook Hosp, Div Neurol, Toronto, ON, Canada
关键词
glioblastoma; chemotherapy; temozolomide; lomustine (CCNU); radiation therapy; ADJUVANT TEMOZOLOMIDE; RADIOTHERAPY; CHEMOTHERAPY; CONCOMITANT; SURVIVAL; REPAIR;
D O I
10.3389/fonc.2020.00066
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:3
相关论文
共 13 条
[1]   Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].
Esteller, M ;
Garcia-Foncillas, J ;
Andion, E ;
Goodman, SN ;
Hidalgo, OF ;
Vanaclocha, V ;
Baylin, SB ;
Herman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354
[2]   Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide [J].
Glas, Martin ;
Happold, Caroline ;
Rieger, Johannes ;
Wiewrodt, Dorothee ;
Baehr, Oliver ;
Steinbach, Joachim P. ;
Wick, Wolfgang ;
Kortmann, Rolf-Dieter ;
Reifenberger, Guido ;
Weller, Michael ;
Herrlinger, Ulrich .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1257-1261
[3]   Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide [J].
Hegi, ME ;
Diserens, AC ;
Godard, S ;
Dietrich, PY ;
Regli, L ;
Ostermann, S ;
Otten, P ;
Van Melle, G ;
de Tribolet, N ;
Stupp, R .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :1871-1874
[4]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[5]   Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 [J].
Herrlinger, Ulrich ;
Rieger, Johannes ;
Koch, Dorothee ;
Loeser, Simon ;
Blaschke, Britta ;
Kortmann, Rolf-Dieter ;
Steinbach, Joachim P. ;
Hundsberger, Thomas ;
Wick, Wolfgang ;
Meyermann, Richard ;
Tan, Ta-Chih ;
Sommer, Clemens ;
Bamberg, Michael ;
Reifenberger, Guido ;
Weller, Michael .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4412-4417
[6]   Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial [J].
Herrlinger, Ulrich ;
Tzaridis, Theophilos ;
Mack, Frederic ;
Steinbach, Joachim Peter ;
Schlegel, Uwe ;
Sabel, Michael ;
Hau, Peter ;
Kortmann, Rolf-Dieter ;
Krex, Dietmar ;
Grauer, Oliver ;
Goldbrunner, Roland ;
Schnell, Oliver ;
Baehr, Oliver ;
Uhl, Martin ;
Seidel, Clemens ;
Tabatabai, Ghazaleh ;
Kowalski, Thomas ;
Ringel, Florian ;
Schmidt-Graf, Friederike ;
Suchorska, Bogdana ;
Brehmer, Stefanie ;
Weyerbrock, Astrid ;
Renovanz, Miriam ;
Bullinger, Lars ;
Galldiks, Norbert ;
Vajkoczy, Peter ;
Misch, Martin ;
Vatter, Hartmut ;
Stuplich, Moritz ;
Schaefer, Niklas ;
Kebir, Sied ;
Weller, Johannes ;
Schaub, Christina ;
Stummer, Walter ;
Tonn, Joerg-Christian ;
Simon, Matthias ;
Keil, Vera C. ;
Nelles, Michael ;
Urbach, Horst ;
Coenen, Martin ;
Wick, Wolfgang ;
Weller, Michael ;
Fimmers, Rolf ;
Schmid, Matthias ;
Hattingen, Elke ;
Pietsch, Torsten ;
Coch, Christoph ;
Glas, Martin .
LANCET, 2019, 393 (10172) :678-688
[7]   Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial [J].
Malmstrom, Annika ;
Gronberg, Bjorn Henning ;
Marosi, Christine ;
Stupp, Roger ;
Frappaz, Didier ;
Schultz, Henrik ;
Abacioglu, Ufuk ;
Tavelin, Bjorn ;
Lhermitte, Benoit ;
Hegi, Monika E. ;
Rosell, Johan ;
Henriksson, Roger .
LANCET ONCOLOGY, 2012, 13 (09) :916-926
[8]   MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges [J].
Mansouri, Alireza ;
Hachem, Laureen D. ;
Mansouri, Sheila ;
Nassiri, Farshad ;
Laperriere, Normand J. ;
Xia, Daniel ;
Lindeman, Neal I. ;
Wen, Patrick Y. ;
Chakravarti, Arnab ;
Mehta, Minesh P. ;
Hegi, Monika E. ;
Stupp, Roger ;
Aldape, Kenneth D. ;
Zadeh, Gelareh .
NEURO-ONCOLOGY, 2019, 21 (02) :167-178
[9]   Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling [J].
Nikolova, Teodora ;
Roos, Wynand P. ;
Kraemer, Oliver H. ;
Strik, Herwig M. ;
Kaina, Bernd .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2017, 1868 (01) :29-39
[10]   Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].
Stupp, R ;
Mason, WP ;
van den Bent, MJ ;
Weller, M ;
Fisher, B ;
Taphoorn, MJB ;
Belanger, K ;
Brandes, AA ;
Marosi, C ;
Bogdahn, U ;
Curschmann, J ;
Janzer, RC ;
Ludwin, SK ;
Gorlia, T ;
Allgeier, A ;
Lacombe, D ;
Cairncross, JG ;
Eisenhauer, E ;
Mirimanoff, RO ;
Van Den Weyngaert, D ;
Kaendler, S ;
Krauseneck, P ;
Vinolas, N ;
Villa, S ;
Wurm, RE ;
Maillot, MHB ;
Spagnolli, F ;
Kantor, G ;
Malhaire, JP ;
Renard, L ;
De Witte, O ;
Scandolaro, L ;
Vecht, CJ ;
Maingon, P ;
Lutterbach, J ;
Kobierska, A ;
Bolla, M ;
Souchon, R ;
Mitine, C ;
Tzuk-Shina, T ;
Kuten, A ;
Haferkamp, G ;
de Greve, J ;
Priou, F ;
Menten, J ;
Rutten, I ;
Clavere, P ;
Malmstrom, A ;
Jancar, B ;
Newlands, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :987-996